BIOVAXY DIVISION OF Merck KGaA BASED GERMANYIn connection with the previously announced acquisition (the “Proposed Transaction”) of BioVaxys, Inc. (“BioVaxys”), the Company is pleased to announce that nonGMP production has been completed on BioVaxys’ SARS-CoV-2 vaccine BVX-0320 (the “Vaccine Candidate”), and dosing has begun with its preclinical study of immune response and T-cell activation in a murine model (the “Murine Mouse Study”). BioVaxys has contracted for the production of the Vaccine Candidate with Millipore/Sigma, a
Division of Merck KGaA based in Darmstadt, Germany. Charles River Laboratories Inc., of Wilmington MA, has been contracted by BioVaxys to perform the preclinical studies of the Vaccine Candidate at varying dosages in the Murine Mouse Study. Upon successful completion of the Murine Mouse Study, BioVaxys anticipates taking further steps to pursue regulatory approval for a study of the Vaccine Candidate in humans. BioVaxys anticipates results from the Murine Mouse Study later this fall and the parties
anticipate completing the Proposed Transaction this month.